Unbalanced estrogen metabolism in ovarian cancer

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2414-2423

  Zahid, Muhammad ^a   Beseler, Cheryl L ^b   Hall, James B ^c   LeVan, Tricia ^a,d,e   Cavalieri, Ercole L ^a   Rogan, Eleanor G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

catechol O methyltransferase; CYP1B1; estrogen DNA adducts; ovarian cancer; SNPs; unbalanced estrogen metabolism

Indexed keywords

CATECHOL METHYLTRANSFERASE; CONJUGATED ESTROGEN; CYTOCHROME P450 1B1; DNA;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA PURIFICATION; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

CATECHOL-O-METHYLTRANSFERASE; CYP1B1; OVARIAN CANCER, ESTROGEN-DNA ADDUCTS, UNBALANCED ESTROGEN METABOLISM; SNPS;

AGED; ARYL HYDROCARBON HYDROXYLASES; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA, NEOPLASM; ESTROGENS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SALIVA; TANDEM MASS SPECTROMETRY;

EID: 84895925640     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28565     Document Type: Article

References (38)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Horner MJ, Ries LAG, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
3. Cavalieri E, Rogan E,. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 2011; 125: 169-80.
4. Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008; 122: 1949-57.
5. Gaikwad NW, Yang L, Pruthi S, et al. Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer: Basic Clin Res 2009; 3: 1-8.
6. Pruthi S, Yang L, Sandhu NP, et al. Evaluation of serum estrogen-DNA adducts as potential biomarkers of breast cancer risk. J Steroid Biochem Mol Biol 2012; 132: 73-9.
7. Zahid M, Goldner W, Beseler C, et al. Unbalanced estrogen metabolism in thyroid cancer. Int J Cancer 2013; 133: 2642-9.
8. Markushin Y, Gaikwad N, Zhang H, et al. Potential biomarker for early risk assessment of prostate cancer. Prostate 2006; 66: 1565-71.
9. Yang L, Gaikwad N, Meza J, et al. Novel biomarkers for risk of prostate cancer. Results from a case-control study. Prostate 2009; 69: 41-8.
10. Gaikwad NW, Yang L, Weisenburger DD, et al. Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 2009; 14: 502-12.
11. Hunn J, Rodriguez GC,. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012; 55: 3-23.
12. Salehi F, Dunfield L, Phillips KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008; 11: 301-21.
13. Beuten J, Gelfond JAL, Byrne JJ, et al. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis 2008; 29: 1751-7.
14. Singh S, Chakravarti D, Edney JA, et al. Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 2005; 14: 1091-6.
15. Hanna IH, Dawling S, Roodi N, et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60: 3440-4.
16. McFadyen MCE, Cruickshank ME, Miller ID, et al. Cytochrome p450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 2001; 85: 242-6.
17. Paracchini V, Pedotti P, Raimondi S, et al. A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med 2005; 43: 702-6.
18. Sellers TA, Schildkraut JM, Pankratz VS, et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2536-43.
19. Delort L, Chalabi N, Satih S, et al. Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 2008; 28: 3079-81.
20. Holt SK, Rossing MA, Malone KE, et al. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 2007; 16: 481-9.
21. Dawling S, Roodi N, Mernaugh RL, et al. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001; 61: 6716-22.
22. Saeed M, Rogan E, Cavalieri E,. Synthesis of the catechols of natural and synthetic estrogens by using 2-iodoxybenzoic acid (IBX) as the oxidizing agent. Steroids 2005; 70: 173-8.
23. Cao K, Stack DE, Ramanathan R, et al. Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine and glutathione. Chem Res Toxicol 1998; 11: 909-16.
24. Stack D, Byun J, Gross ML, et al. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 1996; 9: 851-9.
25. Li K-M, Todorovic R, Devanesan P, et al. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 2004; 25: 289-97.
26. Zahid M, Kohli E, Saeed M, et al. The greater reactivity of estradiol-3,4-quinone versus estradiol-2,3-quinone with DNA in the formation of depurinating adducts. Implications for tumor-initiating activity. Chem Res Toxicol 2006; 19: 164-72.
27. Rylander-Rudqvist T, Hakansson N, Tybring G, et al. Quality and quantity of saliva DNA obtained from the self-administrated Oragene method-a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev 2006; 15: 1742-5.
28. Muthen LK, Muthen BO,. Mplus user's guide. Los Angeles, CA: Muthen & Muthen, 2010.
29. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008; 167: 1059-69.
30. Zhang Y, Coogan PF, Palmer JR, et al. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol 2004; 159: 133-9.
31. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catechol estrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001; 10: 209-16.
32. Chakravarti D, Mailander P, Li K-M, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and form mutations in the H-ras gene. Oncogene 2001; 20: 7945-53.
33. Mailander PC, Meza JL, Higginbotham S, et al. Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol 2006; 101: 204-15.
34. Liehr JG, Fang WF, Sirbasku DA, et al. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986; 24: 353-6.
35. Li JJ, Li SA,. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987; 46: 1858-63.
36. Newbold RR, Liehr JG,. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000; 60: 235-7.
37. Dwivedy I, Devanesan P, Cremonesi P, et al. Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 1992; 5: 828-33.
38. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007; 25: 3596-602.